Pacira Must Pay Exparel Royalties On Its Larger-Scale Process After Partial Court Reversal

The dispute concerns its biggest product and a judgment that brought Pacira $28.3 million in repayment and interest.

Share
Pacira Must Pay Exparel Royalties On Its Larger-Scale Process After Partial Court Reversal

Pacira BioSciences, which develops and sells non-opioid pain treatments, lost part of its court victory Friday when the Ninth Circuit ruled that it owes Exparel royalties on its 200-liter manufacturing process. Pacira described the ruling in an SEC filing Thursday; the decision revisits a dispute in which it received $28.3 million in repayment and interest.

Royalties Return On The 200-Liter Process

The appeals court directed the U.S. District Court for the District of Nevada to rule for Research Development Foundation, Pacira's patent-rights counterparty, on the larger-scale manufacturing claim. It also sent back the portion concerning Exparel made in 45-liter batches so the district court can recalculate interest the foundation owes Pacira.

The agreement required Pacira to pay royalties of a few percent on revenue from certain products while assigned patents remained valid. The foundation can terminate the agreement over an uncured material breach, Pacira's bankruptcy or insolvency, or a challenge by Pacira to those patent rights.

Exparel is central to Pacira's business: its 2025 net sales were $575.1 million, accounting for 79% of total revenue. The long-acting local anesthetic injection is approved for postsurgical pain.

Pacira's other commercial products are Zilretta, an extended-release steroid injection for osteoarthritis knee pain, and iovera, a handheld device that relieves pain by applying cold to a targeted nerve. They generated $116.6 million and $24.2 million in 2025 sales, respectively. The Brisbane, California-based company is also developing PCRX-201, a gene therapy in mid-stage trials for knee osteoarthritis.

A Repayment Victory Faces Revision

Pacira maintains that its royalty obligations ended on December 24, 2021, when an assigned patent expired. The foundation argues that another patent, issued on June 15, 2021, extended payments until 2041.

Pacira sued in December 2021, asking the Nevada district court to declare that it owed no Exparel royalties after the expiration date. In August 2023, it won a ruling ending royalties on the 45-liter process. The larger-scale process went to trial in September 2024, and Pacira won that claim in April 2025.

Those victories eliminated the disputed royalty, and Pacira sought recovery of up to $23.1 million plus interest for payments made under protest. A June 2025 judgment awarded the $23.1 million repayment and $5.2 million in statutory interest. Pacira received $28.3 million in cash in July 2025.

The foundation filed notices of appeal in May and September 2025. Friday's decision partially reversed the district court's judgment, restoring the payment obligation for the 200-liter process while requiring another calculation of interest for the 45-liter portion.

Pacira is evaluating its legal options and intends to defend its rights. The company cautioned that it cannot predict the outcome of the case.

Sources

More on Pacira BioSciences

All Pacira BioSciences (PCRX) coverage →